Equities analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to post earnings of ($0.20) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.09). Sangamo Therapeutics reported earnings per share of ($0.15) in the same quarter last year, which indicates a negative year over year growth rate of 33.3%. The company is expected to announce its next earnings report on Thursday, February 28th.
According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.88) to ($0.61). For the next fiscal year, analysts forecast that the business will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.32) to ($0.49). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. The firm had revenue of $23.56 million during the quarter, compared to analysts’ expectations of $26.96 million. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The firm’s revenue for the quarter was up 99.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.15) earnings per share.
NASDAQ SGMO traded up $0.45 during trading hours on Thursday, hitting $12.37. 1,270,951 shares of the stock were exchanged, compared to its average volume of 2,143,484. The stock has a market capitalization of $1.26 billion, a P/E ratio of -17.67 and a beta of 3.21. Sangamo Therapeutics has a 12-month low of $9.00 and a 12-month high of $27.50. The company has a quick ratio of 6.32, a current ratio of 6.32 and a debt-to-equity ratio of 0.07.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 12,250 shares in the company, valued at $122,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director H Stewart Parker bought 2,000 shares of the stock in a transaction on Friday, September 7th. The shares were bought at an average price of $13.52 per share, for a total transaction of $27,040.00. The disclosure for this purchase can be found here. Insiders have sold 30,000 shares of company stock worth $405,400 over the last 90 days. 1.20% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of SGMO. BlackRock Inc. grew its position in Sangamo Therapeutics by 20.8% during the second quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock worth $114,780,000 after buying an additional 1,391,067 shares during the period. Wasatch Advisors Inc. grew its position in shares of Sangamo Therapeutics by 12.0% in the third quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock valued at $77,031,000 after purchasing an additional 486,429 shares during the last quarter. Credit Suisse AG grew its position in shares of Sangamo Therapeutics by 23.5% in the third quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock valued at $37,027,000 after purchasing an additional 415,764 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Sangamo Therapeutics by 108.6% in the third quarter. Tocqueville Asset Management L.P. now owns 711,237 shares of the biopharmaceutical company’s stock valued at $12,055,000 after purchasing an additional 370,297 shares during the last quarter. Finally, Nexthera Capital LP grew its position in shares of Sangamo Therapeutics by 35.7% in the second quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock valued at $15,150,000 after purchasing an additional 280,538 shares during the last quarter. Institutional investors own 65.90% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Featured Article: Buyback For Investors Defined
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.